EP1571903A1 - Methodes de traitement d'etats pathologiques associes au dysfonctionnement de la signalisation stimulee par l'insuline - Google Patents

Methodes de traitement d'etats pathologiques associes au dysfonctionnement de la signalisation stimulee par l'insuline

Info

Publication number
EP1571903A1
EP1571903A1 EP03795884A EP03795884A EP1571903A1 EP 1571903 A1 EP1571903 A1 EP 1571903A1 EP 03795884 A EP03795884 A EP 03795884A EP 03795884 A EP03795884 A EP 03795884A EP 1571903 A1 EP1571903 A1 EP 1571903A1
Authority
EP
European Patent Office
Prior art keywords
protein
modulator
condition
subject
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03795884A
Other languages
German (de)
English (en)
Inventor
Hao Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Pharma GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH, Novartis AG filed Critical Novartis Pharma GmbH
Priority to EP06118442A priority Critical patent/EP1728424A3/fr
Publication of EP1571903A1 publication Critical patent/EP1571903A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
    • A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
    • A01K67/0337—Genetically modified Arthropods
    • A01K67/0339—Genetically modified insects, e.g. Drosophila melanogaster, medfly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • This invention relates to a method to identify proteins involved in the insulin signaling pathway, methods for identifying compounds useful to treat pathological conditions associated with dysregulation of the insulin signaling pathway as well as to methods and pharmaceutical compositions to treat, prevent or ameliorate conditions associated with dysregulation of the insulin signaling pathway.
  • NIDDM noninsulin-dependent diabetes mellitus
  • the instant application discloses a method to employ transgenic Drosophila to identify proteins involved in the insulin signalling pathway.
  • Human homologs of the Drosophila genes identified according to this method are suitable targets for the development of new therapeutics to treat, prevent or ameliorate pathological conditions associated with the dysregulation of the insulin signaling pathway.
  • the invention relates to a method to identify modulators useful to treat or ameliorate said conditions, including Type II diabetes and the Type A syndrome of insulin resistance comprising a) assaying for the ability of a candidate modulator to modulate the biochemical function of a protein selected from the group consisting of those disclosed in Table 4 or Table 5 and/or modulate gene expression of said protein and which can further include b) assaying for the ability of an identified modulator to reverse the pathological effects observed in animal models of pathological conditions associated with the dysregulation of the insulin signaling pathway and/ or in clinical studies with subjects with said conditions.
  • the invention in another aspect, relates to a method to treat, prevent or ameliorate pathological conditions associated with the dysregulation of the insulin signaling pathway, including Type II diabetes and the Type A syndrome of insulin resistance, comprising administering to a subject in need thereof an effective amount of a modulator of a protein selected from the group consisting of those disclosed in Table 4 or Table 5, wherein said modulator, e.g., inhibits or enhances the biochemical function of said protein.
  • the modulator comprises antibodies to said protein or fragments thereof, wherein said antibodies can inhibit the biochemical function of said protein in said subject.
  • the modulator inhibits or enhances the gene expression of a protein selected from the group consisting of those disclosed in Table 4 or Table 5.
  • the modulator comprises any one or more substances selected from the group consisting of antisense oligonucleotides, triple helix DNA, ribozymes, RNA aptamers, siRNA and double or single stranded RNA wherein said substances are designed to inhibit gene expression of said protein.
  • the invention in another aspect, relates to a method to treat, prevent or ameliorate pathological conditions associated with dysregulation of the insulin signaling pathway, including Type II diabetes and the Type A syndrome of insulin resistance, comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of a modulator of a protein selected from the group consisting of those disclosed in Table 4 or Table 5 .
  • said pharmaceutical composition comprises antibodies to said protein or fragments thereof, wherein said antibodies can inhibit the biochemical function of said protein in said subject and/or any one or more substances selected from the group consisting of antisense oligonucleotides, triple helix DNA, ribozymes, RNA aptamers, siRNA and double or single stranded RNA wherein said substances are designed to inhibit gene expression of said protein.
  • the invention in another aspect, relates to a pharmaceutical composition
  • a modulator to a protein selected from the group consisting of those disclosed in Table 4 or Table 5 in an amount effective to treat, prevent or ameliorate a pathological condition associated with dysregulation of the insulin signaling pathway, including Type II diabetes and the Type A syndrome of insulin resistance, in a subject in need thereof.
  • said modulator may e.g., inhibit or enhance the biochemical functions of said protein.
  • said modulator comprises antibodies to said protein or fragments thereof, wherein said antibodies can, e.g., inhibit the biochemical functions of said protein.
  • said pharmaceutical composition comprises a modulator which may e.g., inhibit or enhance gene expression of said protein.
  • said modulator comprises any one or more substances selected from the group consisting of antisense oligonucleotides, triple helix DNA, ribozymes, RNA aptamers, siRNA or double or single stranded RNA directed to a nucleic acid sequence of said protein wherein said substances are designed to inhibit gene expression of said protein.
  • the invention relates to a method to diagnose subjects suffering from pathological conditions associated with dysregulation of the insulin signaling pathway who may be suitable candidates for treatment with modulators to a protein selected from the group consisting of those disclosed in Table 4 or Table 5 comprising detecting levels of any one or more of said proteins in a biological sample from said subject wherein subjects with altered levels compared to controls would be suitable candidates for modulator treatment.
  • the invention in another aspect, relates to a method to diagnose subjects suffering from pathological conditions associated with dysregulation of the insulin signaling pathway who may be suitable candidates for treatment with modulators to a protein selected from the group consisting of those disclosed in Table 4 or Table 5 comprising assaying mRNA levels of any one or more of said protein in a biological sample from said subject wherein subjects with altered levels compared to controls would be suitable candidates for modulator treatment.
  • a method to treat, prevent or ameliorate pathological conditions associated with dysregulation of the insulin signaling pathway comprising: (a) assaying for mRNA and/or protein levels of a protein selected from the group consisting of those disclosed in Table 4 or Table 5 in a subject; and (b) administering to a subject with altered levels of mRNA and/or protein levels compared to controls a modulator to said protein in an amount sufficient to treat , prevent or ameliorate the pathological effects of said condition.
  • said modulator inhibits or enhances the biochemical function of said protein or gene expression of said protein.
  • kits comprising the components necessary to detect mRNA levels or protein levels of any one or more proteins selected from the group consisting of those disclosed in Table 4 or Table 5 in a biological sample, said kit comprising e.g. polynucleotides encoding any one or more proteins selected from the group consisting of those disclosed in Table 4 or Table 5; nucleotide sequences complementary to said protein; any one or more of said proteins, or fragments thereof of antibodies that bind to any one or more of said proteins, or to fragments thereof.
  • such kits also comprise instructions detailing the procedures by which the kit components are to be used.
  • the present invention also pertains to the use of a modulator to a protein selected from the group consisting of those disclosed in Table 4 or Table 5 in the manufacture of a medicament for the treatment, prevention or amelioration of pathological conditions associated with dysregulation of the insulin signaling pathway, including Type II diabetes and the Type A syndrome of insulin resistance.
  • said modulator comprises any one or more substances selected from the group consisting of antisense oligonucleotides, triple helix DNA, ribozymes, RNA aptamer, siRNA and double or single stranded RNA wherein said substances are designed to inhibit gene expression of said protein.
  • said modulator comprises one or more antibodies to said protein or fragments thereof, wherein said antibodies or fragments thereof can, e.g., inhibit the biochemical function of said protein.
  • the invention also pertains to a modulator to a protein selected from the group consisting of those disclosed in Table 4 or Table 5 for use as a pharmaceutical.
  • said modulator comprises any one or more substances selected from the group consisting of antisense oligonucleotides, triple helix DNA, ribozymes, RNA aptamer, siRNA and double or single stranded RNA wherein said substances are designed to inhibit gene expression of said protein.
  • said modulator comprises one or more antibodies to said protein or fragments thereof, wherein said antibodies or fragments thereof can, e.g., inhibit the biochemical functions of said protein.
  • the invention also pertains to a method to identify proteins involved in the insulin signaling pathway, said method comprising providing a transgenic fly whose genome comprises a DNA sequence encoding a polypeptide comprising the dominant negative PI3K catalytic subunit Dp110° 954A , said DNA sequence operably linked to a tissue specific expression control sequence, and expressing said DNA sequence, wherein expression of said DNA sequence results in said fly displaying a transgenic phenotype compared to controls; crossing said transgenic fly with a fly containing a mutation in a known or predicted gene; and screening progeny of said crosses for flies that carry said DNA sequence and said mutation and display modified expression of the transgenic phenotype as compared to appropriate controls.
  • said DNA sequence encodes Dp11(P 954A and said tissue specific expression control sequence comprises the eye- specific enhancer ey-Gal4 and expression of said DNA sequence results in said fly displaying the "small eye" phenotype.
  • the invention relates to a method to identify drug targets for the development of therapeutics to treat, prevent or ameliorate pathological conditions associated with dysregulation of the insulin signaling pathway, including Type II diabetes and Type A syndrome of insulin resistance, said method comprising identifying the human homologs of the Drosophila proteins identified according to the method discussed above.
  • Figure 1 is a schematic of the eyGal4, UAS, Dpi 10 DN and UASPTEN cross of drosophila transgenes.
  • Figure 2 is a schematic of crosses used for screening X chromosome lethal P- element insertion lines.
  • Figure 3 is a schematic of crosses used for screening second chromosome lethal P- element insertion lines.
  • Figure 4 is a schematic of crosses used for screening third chromosome lethal P- element insertion lines.
  • IRSs insulin receptor substrates.
  • PI3K phosphoinositide 3-kinase.
  • PDKs 3'-phosphoinositide-dependent protein kinases.
  • PTEN phosphatase and tensin homolog deleted from chromosome 10.
  • PKB protein kinase B, also known as Akt1.
  • Stock centers referred to herein include Bloomington and Szeged stock centers which are located at Bloomington, Indiana and Szeged, Hungary, respectively.
  • Nucleic acid sequence refers to an oligonucleotide, nucleotide or polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin that may be single or double stranded, and represent the sense or antisense strand.
  • antisense refers to nucleotide sequences which are complementary to a specific DNA or RNA sequence.
  • antisense strand is used in reference to a nucleic acid strand that is complementary to the "sense" strand.
  • Antisense molecules may be produced by any method, including synthesis by ligating the gene(s) of interest in a reverse orientation to a viral promoter which permits the synthesis of a complementary strand. Once introduced into a cell, this transcribed strand combines natural sequences produced by the cell to form duplexes. These duplexes then block either the further transcription or translation.
  • the designation "negative” is sometimes used in reference to the antisense strand, and "positive” is sometimes used in reference to the sense strand.
  • cDNA refers to DNA that is complementary to a portion of messenger RNA (mRNA) sequence and is generally synthesized from an mRNA preparation using reverse transcriptase.
  • mRNA messenger RNA
  • antisense oligonucleotides, triple helix DNA, RNA aptamers, ribozymes, siRNA and double or single stranded RNA are directed to a nucleic acid sequence such that the nucleotide sequence chosen will produce gene- specific inhibition of gene expression.
  • knowledge of a nucleotide sequence may be used to design an antisense molecule which gives strongest hybridization to the mRNA.
  • ribozymes can be synthesized to recognize specific nucleotide sequences of a gene and cleave it (Cech. J. Amer. Med Assn. 260:3030 (1988)). Techniques for the design of such molecules for use in targeted inhibition of gene expression is well known to one of skill in the art.
  • the individual proteins/polypeptides referred to herein include any and all forms of these proteins including, but not limited to, partial forms, isoforms, variants, precursor forms, the full length protein, fusion proteins containing the sequence or fragments of any of the above, from human or any other species. Protein homologs or orthologs which would be apparent to one of skill in the art are included in this definition. It is also contemplated that the term refers to proteins isolated from naturally occurring sources of any species such as genomic DNA libraries as well as genetically engineered host cells comprising expression systems, or produced by chemical synthesis using, for instance, automated peptide synthesizers or a combination of such methods. Means for isolating and preparing such polypeptides are well understood in the art.
  • sample as used herein, is used in its broadest sense.
  • a biological sample from a subject may comprise blood, urine, brain tissue, primary cell lines, immortilized cell lines, or other biological material with which protein activity or gene expression may be assayed.
  • a biological sample may include, for example, blood, tumors or other specimens from which total RNA may be purified for gene expression profiling using, for example, conventional glass chip microarray technologies such as Affymetrix chips, RT-PCR or other conventional methods.
  • the term "antibody” refers to intact molecules as well as fragments thereof, such as Fa, F(ab') 2) and Fv, which are capable of binding the epitopic determinant.
  • Antibodies that bind specific polypeptides can be prepared using intact polypeptides or fragments containing small peptides of interest as the immunizing antigen.
  • the polypeptides or peptides used to immunize an animal can be derived from the translation of RNA or synthesized chemically, and can be conjugated to a carrier protein. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin and thyroglobulin. The coupled peptide is then used to immunize an animal (e.g., a mouse, goat, chicken, rat or a rabbit).
  • humanized antibody refers to antibody molecules in which amino acids have been replaced in the non-antigen binding regions in order to more closely resemble a human antibody, while still retaining the original binding ability.
  • a “therapeutically effective amount” is the amount of drug sufficient to treat, prevent or ameliorate pathological conditions associated with dysregulation of the insulin signaling pathway.
  • a “transgenic” organism as used herein refers to an organism that has had extra genetic material inserted into its genome.
  • a “transgenic fly” includes embryonic, larval and adult forms of Drosophila that contain a DNA sequence from the same or another organism randomly inserted into their genome. Although Drosophila melanogaster is preferred, it is contemplated that any fly of the genus Drosophila may be used in the present invention.
  • transgene refers to expression of the transgene in a tissue or cell or at a specific developmental stage where it is not normally expressed.
  • phenotype refers to the observable physical or biochemical characteristics of an organism as determined by both genetic makeup and environmental influences.
  • transcription factor refers to any protein required to inititate or regulate transcription in eukaryotes.
  • the eye-specific promoter GMR is a binding site for the eye-specific transcription factor, GLASS (Moses, K and Rubin, GM Genes Dev. 5(4):583-93 (1991)).
  • UAS region refers to an upstream activating sequence recognized by the GAL-4 transcriptional activator.
  • control fly refers to a larva or fly that is of the same genotype as larvae or flies used in the methods of the present invention except that the control larva or fly does not carry the mutation being tested for modification of phenotype.
  • a "transformation vector” is a modified transposable element used with the transposable element technique to mediate integration of a piece of DNA in the genome of the organism and is familiar to one of skill in the art.
  • “elevated transcription of mRNA” refers to a greater amount of messenger RNA transcribed from the natural endogenous gene encoding a protein, e.g. a human protein set forth in Table 4 or Table 5, compared to control levels. Elevated mRNA levels of a protein, e.g. a .
  • human protein disclosed on Table 4 or Table 5 may be present in a tissue or cell of an individual suffering from a pathological condition associated with dysregulation of the insulin signaling pathway compared to levels in a subject not suffering from said condition.
  • levels in a subject suffering from said condition may be at least about twice, preferably at least about five times, more preferably at least about ten times, most preferably at least about 100 times the amount of mRNA found in corresponding tissues in humans who do not suffer from said condition.
  • Such elevated level of mRNA may eventually lead to increased levels of protein translated from such mRNA in an individual suffering from a pathological condition associated with dysregulation of the insulin signaling pathway as compared to levels in a healthy individual.
  • a “Drosophila transformation vector” is a DNA plasmid that contains transposable element sequences and can mediate integration of a piece of DNA in the genome of the organism. This technology is familiar to one of skill in the art.
  • the "small eye phenotype" is characterized by reduced cell size in the eye tissue compared to appropriate controls (Leevers, SJ et al. EMBO J. 1996 Dec 2; 15 (23): 6584-94).
  • transgenic organisms including transgenic Drosophila
  • P-element mediated transformation is Spradling, 1986, "P element mediated transformation", In Drosophila: A practical approach (ed. D. B. Roberts), pp175-197, IRL Press, Oxford, UK.
  • the EP element technology refers to a binary system, utilizing the yeast Gal4 transcriptional activator, that is used to ectopically regulate the transcription of endogenous Drosophila genes. This technology is described in Brand and Perrimon, 1993.
  • a "host cell,” as used herein, refers to a prokaryotic or eukaryotic cell that contains heterologous DNA that has been introduced into the cell by any means, e.g., electroporation, calcium phosphate precipitation, microinjection, transformation, viral infection, and the like.
  • Heterologous as used herein means “of different natural origin” or represent a non-natural state. For example, if a host cell is transformed with a DNA or gene derived from another organism, particularly from another species, that gene is heterologous with respect to that host cell and also with respect to descendants of the host cell which carry that gene. Similarly, heterologous refers to a nucleotide sequence derived from and inserted into the same natural, original cell type, but which is present in a non-natural state, e.g. a different copy number, or under the control of different regulatory elements.
  • a "vector" molecule is a nucleic acid molecule into which heterologous nucleic acid may be inserted which can then be introduced into an appropriate host cell.
  • Vectors preferably have one or more origin of replication, and one or more site into which the recombinant DNA can be inserted.
  • Vectors often have convenient means by which cells with vectors can be selected from those without, e.g., they encode drug resistance genes.
  • Common vectors include plasmids, viral genomes, and (primarily in yeast and bacteria) "artificial chromosomes.”
  • Plasmids generally are designated herein by a lower case p preceded and/or followed by capital letters and/or numbers, in accordance with standard naming conventions that are familiar to those of skill in the art.
  • Starting plasmids disclosed herein are either commercially available, publicly available on an unrestricted basis, or can be constructed from available plasmids by routine application of well known, published procedures.
  • Many plasmids and other cloning and expression vectors that can be used in accordance with the present invention are well known and readily available to those of skill in the art.
  • those of skill readily may construct any number of other plasmids suitable for use in the invention. The properties, construction and use of such plasmids, as well as other vectors, in the present invention will be readily apparent to those of skill from the present disclosure.
  • isolated means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring).
  • a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated, even if subsequently reintroduced into the natural system.
  • Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.
  • transcriptional control sequence or “expression control sequence” refer to DNA sequences, such as initiator sequences, enhancer sequences, and promoter sequences, which induce, repress, or otherwise control the transcription of a protein encoding nucleic acid sequences to which they are operably linked. They may be tissue specific and developmental- stage specific.
  • a “human transcriptional control sequence” is a transcriptional control sequence normally found associated with the human gene encoding a polypeptide set forth in Table 4 of the present invention as it is found in the respective human chromosome.
  • a “non-human transcriptional control sequence” is any transcriptional control sequence not found in the human genome.
  • polypeptide is used interchangeably herein with the terms “polypeptides” and "protein(s)".
  • a "chemical derivative" of a protein set forth in Table 4 or Table 5 of the invention is a polypeptide that contains additional chemical moieties not normally a part of the molecule. Such moieties may improve the molecule's solubility, absorption, biological half life, etc. The moieties may alternatively decrease the toxicity of the molecule, eliminate or attenuate any undesirable side effect of the molecule, etc. Moieties capable of mediating such effects are disclosed, for example, in Remington's Pharmaceutical Sciences, 16th ed., Mack Publishing Co., Easton, Pa. (1980).
  • the ability of a substance to "modulate” a protein set forth in Table 4 or Table 5 includes, but is not limited to, the ability of a substance to inhibit the activity of said protein and/or inhibit the gene expression of said protein. Such modulation could also involve effecting the ability of other proteins to interact with said protein, for example related regulatory proteins or proteins that are modified by said protein.
  • agonist refers to a molecule (i.e. modulator) which, directly or indirectly, may modulate a polypeptide (e.g. a polypeptide set forth in Table 4 or Table 5) and which increase the biological activity of said polypeptide.
  • Agonists may include proteins, nucleic acids, carbohydrates, or other molecules
  • a modulator that enhances gene transcription or the biochemical function of a protein is something that increases transcription or stimulates the biochemical properties or activity of said protein, respectively.
  • Antagonist refers to a molecule (i.e. modulator) which directly or indirectly may modulate a polypeptide (e.g. a polypeptide set forth in Table 4 or Table 5) which blocks or inhibits the biological activity of said polypeptide.
  • Antagonists and inhibitors may include proteins, nucleic acids, carbohydrates, or other molecules.
  • a modulator that inhibits gene expression or the biochemical function of a protein is something that reduces gene expression or biological activity of said protein, respectively.
  • pathological condition associated with dysregulation of the insulin signaling pathway includes, but is not limited to, diabetes, e.g., Type II diabetes, gestational diabetes and the Type A syndrome of insulin resistance.
  • a protein or gene selected from the group consisting of those disclosed in Table 4 or Table 5 refers to the human form of the gene.
  • In vivo models of a pathological condition associated with dysregulation of the insulin signaling pathway include those in vivo models of diabetes familiar to those of skill in the art. Such in vivo models include: an association of the common pro12 allele in PPAR-gamma with type-2 diabetes (Altshuler, D. et al., Nature Genet. 76-80, 2000), defects in the human insulin receptor gene (Kadowaki, T., et al. Science 240: 787-790, 1988), defects in the insulin receptor substrate 1 gene in mouse (Abe, H.; et al., J. Clin. Invest. 101 : 1784-1788, 1998) and defects in glycogen sythase in humans (Groop, L. C et al., New Eng. J. Med. 328: 10-14, 1993).
  • the present invention discloses a method comprising using as a model organism a transgenic fly, Drosophila melanogaster, whose genome comprises a DNA sequence encoding the gene Dp11cP 954A .
  • Conventional expression control systems may be used to achieve ectopic expression of proteins of interest, including the Dpi ⁇ o° 954A peptide. Such expression may result in the disturbance of biochemical pathways and the generation of altered phenotypes.
  • One such expression control system involves direct fusion of the DNA sequence to expression control sequences of tissue-specifically expressed genes, such as promoters or enhancers.
  • a tissue specific expression control system that may be used is the binary Gal4-transcriptional activation system (Brand and Perrimon, Development 118:401-415 (1993)).
  • the Gal4 system uses the yeast transcriptional activator Gal4, to drive the expression of a gene of interest in a tissue specific manner.
  • the Gal4 gene has been randomly inserted into the fly genome, using a conventional transformation system, so that it has come under the control of genomic enhancers that drive expression in a temporal and tissue-specific manner. Individual strains of flies have been established, called “drivers", that carry those insertions (Brand and Perrimon, Development 118:401 -415 (1993)).
  • a gene of interest is cloned into a transformation vector, so that its transcription is under the control of the UAS sequence (Upstream Activating Sequence), the Gal4-responsive element.
  • UAS sequence Upstream Activating Sequence
  • the gene will be expressed in a tissue specific pattern.
  • Gal4 "drivers” that drive expression in later stages of the fly development may be used in the present invention. Using these drivers, expression would result in possible defects in the wings, the eyes, the legs, different sensory organs and the brain.
  • These "drivers” include, for example, aptero ⁇ /s-Gal4 (wings) , elav-Gal4 (CNS), sevenless-Ga ⁇ 4, eye/ess-Gal4 (also called ey-Gal4) and pG/W?-Gal4 (eyes). Descriptions of the Gal4 lines and notes about their specific expression patterns is available in Flybase (http://flybase.bio.indiana.edu) .
  • the construct may contain the Dp11(f 954A sequence cloned into the pUAST vector (Brand and Perrimon, Development 118:401-415 (1993)) which places the UAS sequence upstream of the transcribed region. Insertion of these constructs into the fly genome may occur through P-element recombination, Hobo element recombination (Blackman et al., EMBO J. 8:211-217 (1989)), homologous recombination (Rong and Golic, Science 288:2013-2018 (2000)) or other standard techniques known to one of skill in the art.
  • an ectopically expressed gene may result in an altered phenotype by disruption of a particular biochemical pathway. Mutations in genes acting in the same biochemical pathway are expected to cause modification of the altered phenotype.
  • a transgenic fly carrying both eyeless-Gal4 and UAS- Dp 1 ⁇ o° 954A can be used to identify genes acting in the insulin signalling pathway by crossing this transgenic fly with a fly containing a mutation in a known or predicted gene; and screening progeny of the crosses for flies that display quantitative or qualitative modification of the altered phenotype of the eyeless-Gal4/ Dp110° 954A transgenic fly, as compared to controls.
  • Mutations that can be screened include, but are not limited to, loss-of-function alleles of known genes, deletion strains, "enhancer-trap" strains generated by the P-element and gain-of-function mutations generated by random insertions into the Drosophila genome of a Gal4-inducible construct that can activate the ectopic expression of genes in the vicinity of its insertion. It is contemplated herein that genes involved in the insulin signaling pathway can be identified in this manner and these genes can then serve as targets for the development of therapeutics to treat pathological conditions associated with dysregulation in the insulin signaling pathway.
  • Nucleic acid molecules of the human homologs of the target polypeptides identifed according to the methods of the present invention and disclosed herein may act as target gene antisense molecules, useful, for example, in target gene regulation and/or as antisense primers in amplification reactions of target gene nucleic acid sequences. Further, such sequences may be used as part of ribozyme and/or triple helix sequences or as targets for siRNA or double or single stranded RNA, which may be employed for gene regulation. Still further, such molecules may be used as components of diagnostic kits as disclosed herein.
  • this gene may be used to isolate mutant alleles of the gene. Such isolation is preferable in processes and disorders which are known or suspected to have a genetic basis.
  • Mutant alleles may be isolated from individuals either known or suspected to have a genotype which contributes to disease symptoms related to pathological conditions associated with dysregulation of the insulin signaling pathway, including, but not limited to, conditions such as Type II diabetes or the Type A syndrome of insulin resistance. (Taylor, S.I and Ariogluo, E. (1998) J. Basic Clin. Physiol. Pharmacol. 9, 419-439). Mutant alleles and mutant allele products may then be utilized in the diagnostic assay systems described herein.
  • a cDNA of the mutant gene may be isolated, for example, by using PCR, a technique which is well known to those of skill in the art.
  • the first cDNA strand may be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from tissue known or suspected to be expressed in an individual putatively carrying the mutant allele, and by extending the new strand with reverse transcriptase.
  • the second strand of the cDNA is then synthesized using an oligonucleotide that hybridizes specifically to the 5' end of the normal gene.
  • the product is then amplified via PCR, cloned into a suitable vector, and subjected to DNA sequence analysis through methods well known to those of skill in the art.
  • DNA sequence analysis By comparing the DNA sequence of the mutant gene to that of the normal gene, the mutation(s) responsible for the loss or alteration of function of the mutant gene product can be ascertained.
  • a genomic or cDNA library can be constructed and screened using DNA or RNA, respectively, from a tissue known to or suspected of expressing the gene of interest in an individual suspected of or known to carry the mutant allele.
  • the normal gene or any suitable fragment thereof may then be labeled and used as a probe to identify the corresponding mutant allele in the library.
  • the clone containing this gene may then be purified through methods routinely practiced in the art, and subjected to sequence analysis as described above.
  • an expression library can be constructed utilizing DNA isolated from or cDNA synthesized from a tissue known to or suspected of expressing the gene of interest in an individual suspected of or known to carry the mutant allele.
  • gene products made by the putatively mutant tissue may be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against the normal gene product, as described below.
  • standard antibody screening techniques see, for example, Harlow, E. and Lane, eds., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Press, Cold Spring Harbor).
  • a polyclonal set of antibodies are likely to cross-react with the mutant gene product.
  • Library clones detected via their reaction with such labeled antibodies can be purified and subjected to sequence analysis as described above.
  • nucleic acids comprising a sequence encoding a polypeptide set forth in Table 4, or Table 5 or functional derivatives thereof, may be administered to promote normal biological function, for example, normal insulin mediated signal transduction, by way of gene therapy.
  • Gene therapy refers to therapy performed by the administration of a nucleic acid to a subject.
  • the nucleic acid produces its encoded protein that mediates a therapeutic effect by promoting a normal insulin signaling pathway.
  • the therapeutic comprises a nucleic acid for a Table 4 or Table 5 polypeptide that is part of an expression vector that expresses a Table 4 or Table 5 protein or fragment or chimeric protein thereof in a suitable host.
  • a nucleic acid has a promoter operably linked to the Table 4 or Table 5 protein coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific.
  • nucleic acid molecule in which the Table 4 or Table 5 protein coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the Table 4 or Table 5 nucleic acid (Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; Zijlstra et al., 1989, Nature 342:435-438).
  • Delivery of the nucleic acid into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid-carrying vector, or indirect, in which case, cells are first transformed with the nucleic acid in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.
  • the nucleic acid is directly administered in vivo, where it is expressed to produce the encoded product.
  • This can be accomplished by any of numerous methods known in the art, e.g., by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by infection using a defective or attenuated retroviral or other viral vector (see, e.g., U.S. Pat. No.
  • microparticle bombardment e.g., a gene gun; Biolistic, Dupont
  • coating lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering it in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see e.g., U.S.
  • nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation.
  • the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; W093/14188; and WO 93/20221).
  • the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (see, e.g., U.S. Patents 5,413,923; 5,416,260; and 5,574,205; and Zijlstra et al., 1989, Nature 342:435-438).
  • a viral vector that contains a nucleic acid encoding a Table 4 or Table 5 polypeptide is used.
  • a retroviral vector can be used (see, e.g., U.S. Patents 5,219,740; 5,604,090; and 5,834,182). These retroviral vectors have been modified to delete retroviral sequences that are not necessary for packaging of the viral genome and integration into host cell DNA.
  • the nucleic acid for the Table 4 or Table 5 polypeptide to be used in gene therapy is cloned into the vector, which facilitates delivery of the gene into a patient.
  • Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Methods for conducting adenovirus- based gene therapy are described in, e.g., U.S.
  • Adeno-associated virus has also been proposed for use in gene therapy. Methods for producing and utilizing AAV are described, e.g., in U.S. Patents 5,173,414; 5,252,479; 5,552,311 ; 5,658,785; 5,763,416; 5,773,289; 5,843,742; 5,869,040; 5,942,496; and 5,948,675, all of which are incorporated by reference herein in their entirety.
  • Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection.
  • the method of transfer includes the transfer of a selectable marker to the cells.
  • the cells are then placed under selection to isolate those cells that have taken up and are expressing the transterred gene. Those cells are then delivered to a patient.
  • the resulting recombinant cells can be delivered to a patient by various methods known in the art.
  • epithelial cells are injected, e.g., subcutaneously.
  • recombinant skin cells may be applied as a skin graft onto the patient.
  • Recombinant blood cells e.g., hematopoietic stem or progenitor cells
  • the amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.
  • Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.
  • the cell used for gene therapy is autologous to the patient.
  • the nucleic acid of a polypeptide set forth in Table 4 or Table 5 is introduced into the cells such that it is expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect.
  • stem or progenitor cells are used. Any stem-and/or progenitor cells that can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention.
  • stem cells include but are not limited to hematopoietic stem cells (HSC), stem cells of epithelial tissues such as the skin and the lining of the gut, embryonic heart muscle cells, liver stem cells (see, e.g., WO 94/08598), and neural stem cells (Stemple and Anderson, 1992, Cell 71 :973-985).
  • HSC hematopoietic stem cells
  • epithelial tissues such as the skin and the lining of the gut
  • embryonic heart muscle cells such as the skin and the lining of the gut
  • liver stem cells see, e.g., WO 94/08598
  • neural stem cells Stemple and Anderson, 1992, Cell 71 :973-985.
  • ESCs Epithelial stem cells
  • keratinocytes can be obtained from tissues such as the skin and the lining of the gut by known procedures (Rheinwald, 1980, Meth. Cell Bio. 21 A:229).
  • stratified epithelial tissue such as the skin
  • ESCs or keratinocytes obtained from the skin or lining of the gut of a patient or donor can be grown in tissue culture (Pittelkow and Scott, 1986, Mayo Clinic Proc. 61 :771). If the ESCs are provided by a donor, a method for suppression of host versus graft reactivity (e.g., irradiation, drug or antibody administration to promote moderate immunosuppression) can also be used.
  • HSC hematopoietic stem cells
  • any technique which provides for the isolation, propagation, and maintenance in vitro of HSC can be used in this embodiment of the invention.
  • Techniques by which this may be accomplished include (a) the isolation and establishment of HSC cultures from bone marrow cells isolated from the future host, or a donor, or (b) the use of previously established long-term HSC cultures, which may be allogeneic or xenogeneic.
  • Non-autologous HSC are used preferably in conjunction with a method of suppressing transplantation immune reactions of the future host/patient.
  • human bone marrow cells can be obtained from the posterior iliac crest by needle aspiration (see, e.g., Kodo et al., 1984, J. Clin. Invest. 73:1377- 1384).
  • the HSCs can be made highly enriched or in substantially pure form. This enrichment can be accomplished before, during, or after long-term culturing, and can be done by any techniques known in the art. Long-term cultures of bone marrow cells can be established and maintained by using, for example, modified Dexter cell culture techniques (Dexter et al., 1977, J. Cell Physiol. 91 :335) or Witlock-Witte culture techniques (Witlock and Witte, 1982, Proc. Natl. Acad. Sci. USA 79:3608-3612).
  • the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.
  • a further embodiment of the present invention relates to a method to treat, prevent or ameliorate a pathological condition associated with dysregulation of the insulin signaling pathway that comprises adminstering to a subject in need thereof an effective amount of a modulator of a protein selected from the group consisting of those disclosed in Table 4 or Table 5.
  • the modulator comprises one or more antibodies to said protein, or fragments thereof, wherein said antibodies or fragments thereof can inhibit the biochemical function of said protein in said subject
  • Such antibodies may include, but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') 2 fragments, fragments produced by a Fab expression library, anti- idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.
  • mAbs monoclonal antibodies
  • Such antibodies may be used, for example, in the detection of a target protein in a biological sample, or alternatively, as a method for the inhibition of the biochemical function of the protein.
  • antibodies may be utilized as part of disease treatment methods, and/or may be used as part of diagnostic techniques whereby patients may be tested e.g., for abnormal levels of polypeptides set forth in Table 4 or Table 5, or for the presence of abnormal forms of these polypeptides.
  • various host animals may be immunized by injection with these polypeptides, or a portion thereof.
  • host animals may include but are not limited to rabbits, mice, goats, chickens and rats, to name but a few.
  • adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic poiyois, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum.
  • BCG Bacille Calmette-Guerin
  • Corynebacterium parvum bacille Calmette-Guerin
  • Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen, such as target gene product, or an antigenic functional derivative thereof.
  • an antigen such as target gene product, or an antigenic functional derivative thereof.
  • host animals such as those described above, may be immunized by injection with a Table 4 or Table 5 polypeptide, or a portion thereof, supplemented with adjuvants as also described above.
  • Monoclonal antibodies which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to the hybridoma technique of Kohler and Milstein, (1975, Nature 256:495-497; and U.S. Pat. No. 4,376,110), the human B-cell hybridoma technique (Kosbor et al., 1983, Immunology Today 4:72; Cole et al., 1983, Proc. Natl. Acad. Sci. USA 80:2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies And Cancer Therapy, Alan R.
  • Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof.
  • the hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo. Production of high titers of mAbs in vivo makes this the presently preferred method of production.
  • chimeric antibodies In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci., 81 :6851-6855; Neuberger et al., 1984, Nature, 312:604-608; Takeda et al virgin 1985, Nature, 314:452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used.
  • a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable or hypervariable region derived from a murine mAb and a human immunoglobulin constant region.
  • Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.
  • Antibody fragments that recognize specific epitopes may be generated by known techniques.
  • such fragments include but are not limited to: the F(ab') 2 fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab') 2 fragments.
  • Fab expression libraries may be constructed (Huse et al., 1989, Science, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.
  • an antibody of the present invention can be preferably used in a diagnostic kit for detecting levels of a protein disclosed in Table 4 or Table 5 in a biological sample as well as in a method to diagnose subjects suffering from pathological conditions associated with dysregulation of the insulin signaling pathway who may be suitable candidates for treatment with modulators 10 a protein selected from the group consisting of those disclosed in Table 4 or Table 5.
  • said detecting step comprises contacting said appropriate tissue cell (e.g.
  • sandwich assay of which a number of variations exist, all of which are intended to be encompassed by the present invention.
  • unlabeled antibody is immobilized on a solid substrate and the sample to be tested brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to allow formation of an antibody-antigen binary complex.
  • a second antibody labeled with a reporter molecule capable of inducing a detectable signal, is then added and incubated, allowing time sufficient for the formation of a ternary complex of antibody-antigen-labeled antibody.
  • any unreacted material is washed away, and the presence of the antigen is determined by observation of a signal, or may be quantitated by comparing with a control sample containing known amounts of antigen.
  • Variations on the forward assay include the simultaneous assay, in which both sample and antibody are added simultaneously to the bound antibody, or a reverse assay in which the labeled antibody and sample to be tested are first combined, incubated and added to the unlabeled surface bound antibody.
  • the labeled antibody be an antibody which is specific for a Table 4 or Table 5 polypeptide or a fragment thereof.
  • the most commonly used reporter molecules in this type of assay are either enzymes, fluorophore- or radionuclide-containing molecules.
  • an enzyme immunoassay an enzyme is conjugated to the second antibody, usually by means of glutaraldehyde or periodate.
  • glutaraldehyde or periodate an enzyme is conjugated to the second antibody, usually by means of glutaraldehyde or periodate.
  • Commonly used enzymes include horseradish peroxidase, glucose oxidase, beta-galactosidase and alkaline phosphatase, among others.
  • the substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable color change.
  • p-nitrophenyl phosphate is suitable for use with alkaline phosphatase conjugates; for peroxidase conjugates, 1 ,2-phenylenediamine or toluidine are commonly used.
  • fluorogenic substrates which yield a fluorescent product rather than the chromogenic substrates noted above.
  • a solution containing the appropriate substrate is then added to the tertiary complex.
  • the substrate reacts with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantitated, usually spectrophotometrically, to give an evaluation of the amount of Table 4 or Table 5 polypeptide which is present in the serum sample.
  • fluorescent compounds such as fluorescein and rhodamine
  • fluorescein and rhodamine may be chemically coupled to antibodies without altering their binding capacity.
  • the fluorochrome- labeled antibody When activated by illumination with light of a particular wavelength, the fluorochrome- labeled antibody absorbs the light energy, inducing a state of excitability in the molecule, followed by emission of the light at a characteristic longer wavelength. The emission appears as a characteristic color visually detectable with a light microscope.
  • Immunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotopes, chemiluminescent or bioluminescent molecules may also be employed. It will be readily apparent to the skilled artisan how to vary the procedure to suit the required use.
  • compositions of the present invention may also comprise substances that inhibit the expression of a protein disclosed in Table 4 or Table 5 at the nucleic acid level.
  • Such molecules include ribozymes, antisense oligonucleotides, triple helix DNA, RNA aptamers, siRNA and/or double or single stranded RNA directed to an appropriate nucleotide sequence of nucleic acid encoding such a protein.
  • These inhibitory molecules may be created using conventional techniques by one of skill in the art without undue burden or experimentation. For example, modifications (e.g. inhibition) of gene expression can be obtained by designing antisense molecules, DNA or RNA, to the control regions of the genes encoding the polypeptides discussed herein, i.e.
  • oligonucleotides derived from the transcription initiation site e.g., between positions -10 and +10 from the start site may be used.
  • all regions of the gene may be used to design an antisense molecule in order to create those which gives strongest hybridization to the mRNA and such suitable antisense oligonucleotides may be produced and identified by standard assay procedures familiar to one of skill in the art.
  • triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules.
  • Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. et al. (1994) In: Huber, B.E. and B. I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, N.Y.). These molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.
  • Ribozymes enzymatic RNA molecules, may also be used to inhibit gene expression by catalyzing the specific cleavage of RNA.
  • the mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples which may be used include engineered "hammerhead” or "hairpin” motif ribozyme molecules that can be designed to specifically and efficiently catalyze endonucleolytic cleavage of gene sequences.
  • Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU and GUC.
  • RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable.
  • the suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.
  • Ribozyme methods include exposing a cell to ribozymes or inducing expression in a cell of such small RNA ribozyme molecules (Grassi and Marini, 1996, Annals of Medicine 28: 499-510; Gibson, 1996, Cancer and Metastasis Reviews 15: 287-299). Intracellular expression of hammerhead and hairpin ribozymes targeted to mRNA corresponding to at least one of the genes discussed herein can be utilized to inhibit protein encoded by the gene.
  • Ribozymes can either be delivered directly to cells, in the form of RNA oligonucleotides incorporating ribozyme sequences, or introduced into the cell as an expression vector encoding the desired ribozymal RNA. Ribozymes can be routinely expressed in vivo in sufficient number to be catalytically effective in cleaving mRNA, and thereby modifying mRNA abundance in a cell (Gotten et al., 1989 EMBO J. 8:3861-3866).
  • a ribozyme coding DNA sequence designed according to conventional, well known rules and synthesized, for example, by standard phosphoramidite chemistry, can be ligated into a restriction enzyme site in the anticodon stem and loop of a gene encoding a tRNA, which can then be transformed into and expressed in a cell of interest by methods routine in the art.
  • an inducible promoter e.g., a glucocorticoid or a tetracycline response element
  • tDNA genes i.e., genes encoding tRNAs
  • ribozymes can be routinely designed to cleave virtually any mRNA sequence, and a cell can be routinely transformed with DNA coding for such ribozyme sequences such that a controllable and catalytically effective amount of the ribozyme is expressed. Accordingly, the abundance of virtually any RNA species in a cell can be modified or perturbed.
  • Ribozyme sequences can be modified in essentially the same manner as described for antisense nucleotides, e.g., the ribozyme sequence can comprise a modified base moiety.
  • RNA aptamers can also be introduced into or expressed in a cell to modify RNA abundance or activity.
  • RNA aptamers are specific RNA ligands for proteins, such as for Tat and Rev RNA (Good et al., 1997, Gene Therapy 4: 45-54) that can specifically inhibit their translation.
  • RNA specific inhibition of gene expression may also be achieved using conventional double or single stranded RNA technologies. A description of such technology may be found in WO 99/32619 which is hereby incorporated by reference in its entirety.
  • siRNA technology has also proven useful as a means to inhibit gene expression (Cullen, BR Nat. Immunol. 2002 Jul;3(7):597-9, Martinez, J. et al. Cell 2002 Sept.6;110(5):563).
  • Antisense molecules, triple helix DNA, RNA aptamers, dsRNA, ssRNA, siRNA and ribozymes of the present invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis.
  • RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding the genes of the polypeptides discussed herein. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6.
  • cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells, or tissues.
  • Vectors may be introduced into cells or tissues by many available means, and may be used in vivo, in vitro or ex vivo.
  • vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection and by liposome injections may be achieved using methods that are well known in the art.
  • Detection of mRNA levels of proteins disclosed herein may comprise contacting a biological sample or even contacting an isolated RNA or DNA molecule derived from a biological sample with an isolated nucleotide sequence of at least about 20 nucleotides in length that hybridizes under high stringency conditions (e.g. 0.1 x SSPE or SSC, 0.1% SDS, 65°C) with the isolated nucleotide sequence encoding a polypeptide set forth in Table 4 or Table 5.
  • Hybridization conditions may be highly stringent or less highly stringent.
  • nucleic acid molecules are deoxyoligonucleotides ("oligos")
  • highly stringent conditions may refer, e.g., to washing in 6X SSC/0.05% sodium pyrophosphate at 37 °C (for 14-base oligos), 48 °C (for 17-base oligos), 55 °C (for 20-base oligos), and 60 °C (for 23-base oligos).
  • Suitable ranges of such stringency conditions for nucleic acids of varying compositions are described in Krause and Aaronson (1991), Methods in Enzymology, 200:546-556 in addition to Maniatis et al., cited above.
  • detection of a mutated form of the gene which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under- expression, over-expression or altered spatial or temporal expression of the gene.
  • Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.
  • Nucleic acids, in particular mRNA, for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material.
  • the genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis.
  • RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype . Point mutations can be identified by hybridizing amplified DNA to labeled nucleotide sequences encoding a polypeptide encoded by a gene disclosed in Table 4 or Table 5. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures.
  • DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (e.g., Myers et al., Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton et al., Proc Natl Acad Sci USA (1985) 85: 4397-4401).
  • an array of oligonucleotides probes comprising nucleotide sequence encoding the Table 4 or Table 5 polypeptides or fragments of such nucleotide sequences can be constructed to conduct efficient screening of e.g., genetic mutations.
  • the diagnostic assays offer a process for diagnosing or determining a susceptibility to disease through detection of mutation in the gene of a polypeptide set forth in Table 4 or Table 5 by the methods described.
  • diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods.
  • Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art.
  • assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.
  • the present invention relates to a diagnostic kit for detecting mRNA levels (or protein levels) which comprises:
  • kits may comprise a substantial component.
  • a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly to a disease or condition associated with dysregulation of the insulin signaling pathway, for example, Type II diabetes or the Type A syndrome of insulin resistance.
  • the nucleotide sequences of the present invention are also valuable for chromosome localization.
  • the sequence is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome.
  • the mapping of relevant sequences to chromosomes is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available online through Johns Hopkins University Welch Medical Library).
  • genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).
  • linkage analysis coinheritance of physically adjacent genes.
  • the differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.
  • compositions may comprise, for example, a polypeptide set forth in Table 4 or Table 5, antibodies to that polypeptide, mimetics, agonists, antagonists, inhibitors or other modulators of function of a Table 4 or Table 5 polypeptide or gene therefore.
  • the compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water.
  • the compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.
  • any of the therapeutic proteins, antagonists, antibodies, agonists, antisense sequences or other modulators described above may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles.
  • the combination of therapeutic agents may act synergistically to effect the treatment, prevention or amelioration of pathological conditions associated with abnormalities in the insulin signaling pathway. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.
  • Antagonists, agonists and other modulators of the human polypeptides set forth in Table 4 or Table 5 and genes encoding said polypeptides may be made using methods which are generally known in the art.
  • compositions encompassed by the invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-articular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.
  • these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa.).
  • compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration.
  • Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.
  • compositions for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen.
  • disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.
  • Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • suitable coatings such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.
  • Push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol.
  • Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers.
  • the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.
  • compositions suitable for parenteral administration may be formulated m aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline.
  • Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • suspensions of the active compounds may be prepared as appropriate oily injection suspensions.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
  • Non-lipid polycationic amino polymers may also be used for delivery.
  • the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • penetrants appropriate to the particular barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art.
  • the pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.
  • the pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.
  • the preferred preparation may be a lyophilized powder that may contain any or all of the following: 1-50 mM histidine, 0. 1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.
  • compositions After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. Such labeling would include amount, frequency, and method of administration.
  • compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose.
  • the determination of an effective dose is weU within the capability of those skilled in the art.
  • the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs.
  • the animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • a therapeutically effective dose refers to that amount of active ingredient which ameliorates the symptoms or condition.
  • Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50.
  • Pharmaceutical compositions which exhibit large therapeutic indices are preferred.
  • the data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use.
  • the dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
  • the exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors that may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.
  • Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration.
  • Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc. Pharmaceutical formulations suitable for oral administration of proteins are described, e.g., in U.S.
  • All flies are kept on standard corn meal food according to methods familiar to one of skill in the art. Using conventional methods, all crosses are done at 25°C. Balancers, or special chromosomes that prevent recombination and carry at least one dominant morphological marker are used and include CyO, TM3 and TM6B. All flies used carry the w 1118 mutant allele at the white locus. Mutations not referenced herein and the nomenclatures of standard Drosophila genetics have been described previously and are familiar to one of skill in the art (Lindsley, D. L., and Zimm, G. (1992). The Genome of Drosophila melanogaster (New York: Academic Press); http://flybase.bio.indiana.edu ).
  • the ey-Gal4 (also referred to as "eyeless-Gal4") strain is obtained from Bloomington stock center (Bloomington, IL). In this strain, the yeast transcription factor Gal4 is expressed in the precursor cells and adult cells of fly eyes. UAS- Dp110° 954A and UAS-PKB strains are used (Leevers et al, EMBO J. 1996 Dec 2;15(23):6584-94; Staveley, et al. Curr Biol. 1998 May 7;8(10):599-602). EP insertion strains are obtained from Bloomington and Szeged stock centers.
  • the generation of a recombinant second chromosome that bears both the ey- Gal4 and UAS- Dp11cf 954A transgenes is described below: the w; ey-Gal4/CyO flies are crossed to y w; UAS-Dp110° 954A flies. Virgin daughters of the genotype w/y w; ey-Gal4/ UAS- Dp11cP 954A are crossed to w/Y; Sp/CyO; MKRS,ry/TM2, ry males.
  • a male progeny with the genotype w/Y; ey-Gal4, UAS-Dp110° 954A /CyO; MKRS,ry/TM2, ry /+ is selected based on small eye phenotype and crossed to w/w; Sp/CyO; MKRS, ry/TM2, ry virgin females to establish w; ey-Gal4, UAS-Dp110° 954A /CyO; MKRS,ry/TM2, ry/+ stock.
  • Crosses used for the screening of the X chromosome EP insertion lines are described below: Males of the X chromosome EP insertion lines (EP(X)) are crossed to w; ey-Ga!4, UAS-Dp11 cP 954A /CyO; MKRS, ry/TM2, ry /+ females. Adult progenies of the genotype EP(X)/w; ey-Gal4 UAS-Dp110° gs4A /+ w/Y ey-Gal4, UAS-Dp110° 9S4A /+ are selected for comparison.
  • Flies are examined under a Zeiss dissecting microscope (Carl Zeiss Microlmaging, Inc. ,Thornwood, NY). The eyes of at least five EP(X)/w; ey-Gal4 UAS-Dp11 cP 954A /+ flies were compared to the eyes of at least five w/Y; ey-Gal4, UAS-Dp110° 954A /+ (see above). If the average eye sizes of the two fly groups are significantly different upon visual inspection, the EP(X) line is selected as a potential positive. Statistical analysis is then performed by measuring the eye size of larger number of flies (see below).
  • the crosses used for the screening of the second chromosome EP insertion lines is described below: Either males or virgin females of the second chromosome EP insertion lines (EP(2)) are crossed to w; ey-Gal4, UAS-Dp110° 954A /CyO; MKRS,ry/TM2, ry /+ virgin females or males.
  • the eyes of at least five ey-Gal4, UAS- Dp11(f 954A /CyO progeny flies are compared to the eyes of at least 5 ey-Ga!4, UAS- Dp1 i( 9S4A /EP(2) progeny flies with the same sex.
  • the same criterion was used to select potential positive EP(2) lines as in the case of EP(X) lines.
  • Statistical analysis is also used to confirm the positives.
  • Crosses using the third chromosome EP insertion lines The crosses used for the screening of the third chromosome EP insertion lines is described below:
  • the EP(3) lines obtained from stock centers are balanced either by TM3 or TM6B balancers.
  • Either males or virgin females of the third chromosome EP insertion lines (EP(3)) are crossed to w; ey-Gal4, UAS-Dp11(P 9S4A /CyO; MKRS,ry/TM2, ry /+ virgin females or males.
  • the eyes of at least five ey- Gal4, UAS-Dp110° 954A /+; EP(3)/+ progeny flies are compared to the eyes of at least five ey-Gal4, UAS-Dp11( 954A /+; balancer/+ progeny flies with the same sex.
  • the same criterion is used to select potential positive EP(3) lines as in the case of EP(X) lines.
  • Statistical analysis is used to verify the positive lines.
  • the Student's t-Test (one- tailed, two-sample unequal variance) is used to test if there is statistically significant (p ⁇ 0.05) difference between the mean eye size of two genotypes.
  • the eye size data or its log transformation is tested for normality using the Kolmogorov-Smirnov test (Sokal, R.R. and Rohlf, F.J. (1981) Biometry. W.H. Freeman and Company, New York. 716pp.).
  • SigmaStat for Windows Version 2.03 SPSS, Inc. Chicago, IL is used for statistical analysis of fly eye size.
  • the other genetic technique used is EP element mutagenesis (Rorth, P., et al. 1998 Development 125, 1049-57).
  • the EP element is a synthetic, modified P element containing UAS sequences and a basal promoter at one end.
  • the EP element can randomly insert into the Drosophila genome, often at the 5' end of a gene. Because the EP element is asymmetric with only one end containing the UAS sequence and a basal promoter, the effect of an EP insertion on nearby genes is influenced by the orientation of the inserted EP element.
  • a N6 random primer (Roche Applied Science, Indianapolis, IN ) is used for the reverse transcription reaction.
  • the primer pairs and probe for each transcription unit is commercially available from Applied Biosystems (Foster City, CA).
  • Real-time PCR is done using the ABl Prism 7700 Sequence Detection System according to the manufacturer's instruction (Applied Biosystems).
  • Primer concentrations are 0.2 pmol/ul and the probe concentration is 0.1 uM, in a 25ul reaction. Cycles are 50°C for 2min, 95°C for 10min, followed by 40 cycles of 95°C for 15sec, 60°C for 1min.
  • RNA levels are normalized by using the endogenous RNA levels of the ribosomal protein rp49 gene in each sample according to conventional methods.
  • EP/+ virgin females are crossed to hspGal4/CyO males.
  • Male progenies of the genotype EP/Y; hspGal4/+ are collected and made to 8 vials with 10 flies per vial.
  • RNAs are prepared from the 10 flies from each heat-shocked vial after heat shock and from unheat-shocked vials.
  • Male progenies of the genotype + Y; hspGal4/+, the genotype EP/Y; +/CyO, the genotype +/Y; +/CyO are similarly treated and total RNAs prepared.
  • hs refers to heat shock and nhs is no heat shock
  • the Student t-Test is used to determine if there is statistical difference between value A and A'. If there is a difference, it would indicate that there is a heat shock-dependent effect which may act through the interaction between Gal4 and EP.
  • the ratio of (A7A)/((B7B+C7C+D7D)/3) is determined and used to indicate the Gal4- dependent effect of EP on the transcription unit RNA level. (See Table 4, column "Gal4 effect”).
  • the EP insertion may disrupt the function of a cis regulatory element of a nearby transcription unit at the insertion point. This insertion-effect is independent of Gal4. (See Table 4, column "Insert effect”).
  • Student t-Test is used to determine if there is a statistical difference between value C and D. If there is a difference, the ration of C/D is used to indicate the insertion- effect of a EP on a transcription unit RNA level.
  • the same method is used to analyze the second chromosome and third chromosome EP lines.
  • the small eye phenotype-based genetic modifier screen we reasoned that the phenotype must be modifiable by changing the expression level of known insulin signaling genes. This is indeed what we observed.
  • the small eye phenotype is suppressed by over-expression of Drosophila PKB via the UAS-PKB transgene, which acts downstream of PI3K.
  • the small eye phenotype is also enhanced by over-expression of PTEN, which acts antagonistically to PI3K (See also Goberdhan, D. C. et al.(1999) Genes Dev 13, 3244-58.; Huang, H., et al., Development 126, 5365-72.).
  • flies carrying a chromosome with both the ey-Gal4 and the UAS-Dp110° 954A transgenes have smaller eyes as compared to wild type control flies.
  • This small eye phenotype has 100% penetrance, indicating strong inhibitory effect of the Dpi 10 D954A protein in the insulin pathway.
  • the Drosophila genome contains about 14,000 predicted genes (Adams et al., 2000 Science 2872185-95). These genes are defined by the predicted transcripts (sometimes referred to as transcription units or "Celera Transcripts" (CTs or CGs), see www.Celera.com). Based on the known functions and predicted functions, these genes or transcription units are classified into different functional categories or "bins”.
  • An analysis of publicly available EP strains revealed 1536 EP strains that have EP elements inserted within 10 Kb distance upstream from the start codon (ATG) of 483 genes (CTs).
  • genes belong to the functional bins of peptidase, protein kinases/phophatases, signal transduction molecules, transporters, ligand-binding proteins, transcription factors, enzymes and other types of molecules.
  • the functional bin categories are based on the Celera Drosophila Jamboree Release 1.
  • EP(3)3553 is a suppressor of Dp11(f 954A
  • the mean eye size of the XX; ey-Gal4 UAS-Dp1 ⁇ 954A /+ flies is 8.39x10 "2 mm 2 while the mean eye size of their sisters XX; ey-Gal4 UAS-Dpl 1(f 954A /+; EP(3)3553/+ flies is 1.19x10 "1 mm 2 .
  • the two means are significantly different (p ⁇ 0.001 , Student's t-Test hereafter).
  • Genotypes Mean 5 S.D. n" eye size, mm 2
  • the abbreviated progeny genotypes of the cross X/Y; +/+; BP(3)3553/TM6B,Tb x X X; ey-Gal4, UAS-Dp11cP 954A /CyO; +/+. TM6B and CyO are balancer chromosomes ( se methods section, above).
  • the means of Row 3 and Row 4 differ at the significant level with p ⁇ 0.001.
  • c. S.D. represents standard deviation.
  • d. The total number of eyes measured.
  • EP(3)3553 has an EP element inserted on the third chromosome at the 5' end noncoding sequences of the Drosophila gene Pk61C, which is the fly ortholog of mammalian PDK1 , Genbank accession number NM_002613 (http://flvbase.bio.indiana.edu.).
  • Pk61C is the only gene found within 10 Kb region on both sides of the EP(3)3553 insertion site.
  • the relative position of the Pk61C gene to the EP(3)3553 element is such that the 5' end of Pk61C is proximal to the UAS-containing end of the EP(3)3553 element (http://flvbase.bio.indiana.edu).
  • GAL4 would induce the expression of Drosophila PDK1. Since PDK1 is known to act downstream of PI3K in the insulin signaling pathway, it is also predicted that over-expression of PDK1 might suppress DpHcP ⁇ -mduced phenotypes. Thus, given the involvement of PDK1 in the insulin signaling pathway, the identification of EP(3)3553 as a suppressor of Dpi 1 CP 594A - ⁇ n ⁇ ced small eye phenotype strongly suggests that our genetic screen can be used to identify molecules relevant to the insulin pathway.
  • EP(X)0382 significantly suppresses the small eye phenotype induced by over-expression of Dp11(P 954A .
  • the mean eye size of EP(X)0382 X; ey-Gal4, (1.04x10 "1 mm 2 ) is significantly larger than that of the XX; ey-Gal4, UAS-Dp11cP 954A /+ flies (9.05x10 "2 mm 2 ; p ⁇ 0.0001), indicating that EP(X)0382 suppresses the function of Dp11( 954A . See Table 2 below:
  • EP(X)0382 suppresses Dp11( '954A
  • Row 1 and 2 contain the abbreviated genotypes of the stock wfY; ey-Gal4, UAS- Dpl 1( 954A /CyO.
  • Rows 3-4 contain the abbreviated progeny genotypes of the cross EP(X)0382/Y; +/+ x w/w; ey-Gal4, UAS-Dp11(f 954A /CyO. CyO ls a balancer chromosome (see methods section, above).
  • Flies in Rows 1 -2 are siblings.
  • Flies in Rows 3-4 are siblings. But flies in Rows 1-2 are not siblings of flies in Rows 3-4. Therefore, they could have experienced somewhat different growth conditions which affect the body size including eye size.
  • the measured eye sizes of Rows 3-4 are corrected, based on the assumption that the flies of the common genotype XY; ey-Gal4, UAS-Dp11(P 954A /+ (Row 2, Column 1 ; Row 4, Column 1) should have the same mean eye size.
  • Each of the 20 eyes measured in Rows 3-4 are corrected by the factor 0.981 (7.24x10 "2 /7.38x10 "2 , see Column 2). This column shows the average of the corrected eye sizes. Student's t-Test shows that the means of Row 1 and Row 3 differ at the significant level with p ⁇ 0.001.
  • the standard deviation is based on the corrected eye sizes.
  • EP(X)0382 strain has an EP element inserted on the X chromosome at the 5' end of the Drosophila gene corkscrew (csw), which is the fly ortholog of the human protein-tyrosine phosphatase SHP-2 gene (GenBank accession number NM_002834).
  • the insertion site is 201 nucleotides upstream of the start site of a cswcDNA (GenBank Accession U19909; www.fruitfly.org).
  • the relative position of the csw gene to the EP(X)0382 element is such that the 5' end of csw is proximal to the non-UAS-containing end of the EP(X)0382 element.
  • Using quantitative real-time RT-PCR no effect of the EP on csw RNA level was detectable at the level of analysis.
  • EP(3)3459 The suppression of the small eye phenotype by EP(3)3459 is statistically significant.
  • the presence of EP(3)3459 insertion increases the mean eye size of ey-Gal4, UAS-Dp11cP 954A /+ i ⁇ es (9.71 x10 '2 mm 2 versus 9.09x10 "2 mm 2 in XX flies, p ⁇ 0.05; 8.10x10 "2 mm 2 versus 7.13x10 "2 mm 2 in XY flies, p ⁇ 0.003). See Table 3 below.
  • Genotypes 3 Mean 0 S ⁇ n
  • EP(3)3459/T 6B,Sj ,Tb x X/X; ey-Gal4, UAS-Dp110° 954A /CyO; +/+. TM6B and CyO are balancer chromosomes (see methods section above) b.
  • Student's t-Test shows that the means of Row 1 and Row 2 differ at the significant level with p ⁇ 0.05.
  • the means of Row 3 and Row 4 differ at the significant level with p ⁇ 0.003.
  • EP(3)3459 strain has an EP element inserted on the third chromosome at about 5 Kb upstream from the 5' end of the Drosophila casein kinase ll-alpha subunit interactor-3 (Ckll- ⁇ -i3, Genbank accession number AF090440).
  • the 5' end of Ckll- ⁇ -i3 is proximal to the non-UAS-containing end of the EP(3)3459 element.
  • no gene was found within the 10 Kb region.
  • Quantitative RT-PCR (Taqman) experiments indicate that this EP element causes 4 fold loss-of-expression of Ckll- ⁇ -i3.
  • the human homolog of Ckll- ⁇ -i3 is suspected to be the human KIAA0336 gene (GenBank accession number AB002334) Nagase, T., et al. (1997) DNA Res 4, 141-50.
  • the KIAA0336 gene encodes a protein with 1583 amino acid residues with no known function.
  • the cDNA that defines K7A40336 was derived from brain tissue.
  • the KIAA0336 gene is expressed in all tissue categories except the stomatognathic system based on LifeSeq®Gold 5.1. It has the highest expression in the hemic and immune system, as judged by the percentage of KIAA0336 gene-derived cDNA clones among the total number of sequenced cDNA clones from the hemic and immune system.
  • the apparent lack of the KIAA0336 gene-derived cDNA clones in the stomatognathic system libraries may be due to the lower number of sequenced cDNA clones (10,988) from the libraries of the stomatognathic system as compared to 648,215 sequenced clones from the libraries of the hemic and immune system.
  • Ckll- ⁇ -i3 was identified through a two-hybrid interaction with CKll ⁇ subunit (see also the Genbank annotation, Genbank accession number AF090440). It encodes a putative nuclear protein with CKll consensus phosphorylation sites. While the function of Ckll- ⁇ -i3 has not been reported, CKll is likely involved in the insulin signaling pathway based on data which shows that a CKll inhibitor blocks the insulin- induced DNA-binding activity of nuclear extracts and the CKll a subunit interacts with the insulin receptor substrate-1 (IRS-1) in vitro ( Kim, S. J., and Kahn, C. R. (1997) Biochem J 323, 621-7.; Li et al., 1999).
  • IRS-1 insulin receptor substrate-1
  • the human ortholog of Ckll-a-i3 , KIAA0336 plays a role in the insulin signaling pathway, and as such is a suitable drug target for the development of therapeutics to treat, prevent or ameilorate pathological conditions associated with the dysregulation of the insulin signaling pathway.
  • PI3K Drosophila phosphoinositide 3-kinase
  • Another mutation is linked to the Drosophila ortholog of the protein-tyrosine phosphatase SHP-2 gene. Both PDK1 and SHP-2 are known genes in the mammalian insulin signaling pathway, suggesting that the screen will identify molecules relevant to human diabetes.
  • the third mutation is linked to the Drosophila gene Ckll- ⁇ -i3, whose human ortholog is KIAA0336.
  • proteins were identified which are suspected to play a role in the insulin signaling pathway. These genes and their human homologs (listed in column “best hu”) (as well as KIAA0336, discussed above) are set forth below in Table 4.
  • the genetic screen identified the suppressors, which were divided into categories depending on strength of suppression, where S1 is the strongest and S4 the weakest, ND is not determined.
  • FMR2 protein EP(2)2172 S1 S1 CG8817(lilli) no 0.53X N _002025 1.E-14 nucleoside diphosphatase (ER-UDPase) EP(2)2172 S1 S1 CT10292 2.2x 0.79x
  • CSP CYSTEINE STRING PROTEIN
  • DNA binding protein transglycos sidases EP(3)3097 S2 S2 CG7187 ND ND NM_018070.2 5.00E-47
  • SH3/SH2 adaptor protein SAM pointed EP(3)3474 S3 S2 CG31163 ND ND NM_015278.1 3.00E-31 domain casein kinase I, gamma 3 activity EP(3)3652 S1 S2 CG6963 ND ND NM_004384.1 1.00E-170
  • FMR2 protein EP(2)2172 S1 S1 CG8817(lilli) no 0.53X NM_002025 1.E-14 nucleoside diphosphatase (ER-UDPase) EP(2)2172 S1 S1 CT10292 2.2x 0.79X
  • CSP CYSTEINE STRING PROTEIN
  • TRANSCRIPTION FACTOR ADF-1 (ADH EP(3)3354 S1 S1 CT16251 36x no none DISTAL FACTOR 1) membrane protein TMS-2 EP(3)3355 S1 S1 CT15063 7x no AB033079.1 6.E-90 unknown EP(3)3355 S1 S1 CT14836(failed no 0.05X XM 046613.1 4.E-22 axon connection)
  • a modifier gene a protein (gene listed in Table 4 ) (i.e. "a modifier gene") is involved in insulin signaling and metabolism, one may examine if the perturbation of a modifier gene will cause a change in the expression level of an insulin responsive sequence (IRS)-controlled reporter gene.
  • IRS insulin responsive sequence
  • the activation of the insulin signaling pathway leads to the inhibition of the forkhead transcription factors that bind to the insulin responsive sequences.
  • changes in the insulin signaling level by a modifier may lead to changes in the expression level of the IRS-controlled genes.
  • the insulin signaling pathway controls glucose and lipid metabolism, one may examine if the perturbation of a modifier gene causes a change in the glycogen or lipid level in the fly.
  • the genetic screen is designed to identify both genes that activate and the genes that repress the insulin signaling pathway. However, because stimulating the insulin signaling pathway is needed for the treatment of diabetes, the genes that normally inhibit insulin signaling may be the preferred drug targets.
  • a similar genetic screening method may also be developed using an additional known gene in the insulin signaling pathway, PTEN, a negative regulator of the ISP.
  • Over-expression of PTEN in developing eyes also causes a small eye phenotype, and the eye phenotype observed following Dpi 10 DN overexpression in the eye is further enhanced by over-expression of PTEN.
  • This double-mutant transgenic fly stock capable of overexpression of both Dpi 10 DN and PTEN is maintained in the presence of a tub:Gal80 transgene.
  • the constitutive expression of Gal ⁇ O from this transgene binds to Gal4 protein, blocking Gal4-mediated transcriptional activation. This in turn stops the accumulation of genetic modifiers that ameliorate the reduction in viability associated with overexpression of components of the ISP.
  • a suppressor screen may be established.
  • the enhanced small eye phenotype is better suited for a screen in which the expected 2-fold reduction in gene product associated with heterozygosity for loss-of-function mutations would produce a noticeable suppression of the phenotype, i.e. insertion mutations that would be haplo-insufficient with respect to the sensitized ISP phenotype resulting from co-overexpression of both Dpi 10 DN and PTEN.
  • the P-elements screened are of two types.
  • the first type of P-element contains a mini white gene( mw) and results in a ' red eye phenotype when expressed in a white 1118 background.
  • the second type of P-element contains a mini rosy gene (rw) that when expressed in a white plus and rosy minus background results in a rosy eye phenotype.
  • the fly stocks that contain the eyGal4, UAS Dpi 10 DN , UASPTEN, and tubGal ⁇ O must be contained within the two backgrounds so that the P-elements can be witnessed when introduced.
  • the eyGal4, UAS Dp110 DN , and UASPTEN transgenes all reside on the second chromosome and may be recombined together as shown in Figure 1.
  • Tub-Gal80 can be accessed publicly through the Bloomington Stock Centre.
  • the transgene mutant available is on the X chromosome.
  • the transgene is transposed to a new position on the CyO Balancer Chromosome using standard drosophila transposition crosses.
  • the tub-Gal80 CyO is then put into the whitel 118 background as well as the rosy minus background and balanced over Sco second balancer chromosome.
  • the tub-Gal80 CyO stocks are then crossed with the eyGal4, UAS Dpi 10 DN , UASPTEN / CyO stocks creating eyGal4, UAS Dpi 10 DN , UASPTEN / tub-Gal80 CyO. These are done in the white 1118 background as well as the rosy minus background.
  • new genetic screening methods may also be developed using other known genes in the insulin signaling pathway. Screens such as those described above are especially desirable since they are a "selection"-based screen.
  • a fluorescent reporter- based genetic screen may also be used. The advantage of this approach is that it is adaptable for high throughput automation. For example, it is known that the insulin pathway controls the activity of the FKHR-type forkhead transcription factors. A fluorescent reporter can be made using the forkhead binding sites to control flourescent marker expression. Flies carrying this reporter screened with a fluorescent Drosophila larvae sorter would be an efficient system to identify new genes in the insulin pathway

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention se rapporte à une méthode permettant d'identifier des protéines impliquées dans la voie de signalisation stimulée par l'insuline. L'invention concerne également des cibles appropriées pour la mise au point de nouvelles thérapies permettant de traiter, prévenir ou améliorer des états pathologiques associés au dysfonctionnement de la voie de signalisation stimulée par l'insuline. L'invention se rapporte en outre à des méthodes de traitement, de prévention ou d'amélioration desdits états et à des compositions pharmaceutiques ainsi qu'à une méthode permettant d'identifier des composés à utilité thérapeutique dans le but de traiter les états pathologiques associés au dysfonctionnement de la voie de signalisation simulée par l'insuline.
EP03795884A 2002-12-12 2003-12-11 Methodes de traitement d'etats pathologiques associes au dysfonctionnement de la signalisation stimulee par l'insuline Withdrawn EP1571903A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06118442A EP1728424A3 (fr) 2002-12-12 2003-12-11 Méthode pour le traitement de maladies liées à la dérégulation du système de signalisation de l'insuline

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43285402P 2002-12-12 2002-12-12
US432854P 2002-12-12
PCT/EP2003/014078 WO2004052094A1 (fr) 2002-12-12 2003-12-11 Methodes de traitement d'etats pathologiques associes au dysfonctionnement de la signalisation stimulee par l'insuline

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP06118442A Division EP1728424A3 (fr) 2002-12-12 2003-12-11 Méthode pour le traitement de maladies liées à la dérégulation du système de signalisation de l'insuline

Publications (1)

Publication Number Publication Date
EP1571903A1 true EP1571903A1 (fr) 2005-09-14

Family

ID=32508000

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03795884A Withdrawn EP1571903A1 (fr) 2002-12-12 2003-12-11 Methodes de traitement d'etats pathologiques associes au dysfonctionnement de la signalisation stimulee par l'insuline

Country Status (4)

Country Link
EP (1) EP1571903A1 (fr)
JP (1) JP2006509795A (fr)
AU (1) AU2003298176A1 (fr)
WO (1) WO2004052094A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078940A1 (fr) * 1999-06-22 2000-12-28 Universität Zürich Systeme modele d'insecte in vivo pour le diabete de type ii
WO2002043760A1 (fr) * 2000-12-01 2002-06-06 Sumitomo Pharmaceuticals Co., Ltd. Activateurs du metabolisme du sucre

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004052094A1 *

Also Published As

Publication number Publication date
JP2006509795A (ja) 2006-03-23
AU2003298176A1 (en) 2004-06-30
WO2004052094A1 (fr) 2004-06-24

Similar Documents

Publication Publication Date Title
EP1352961B1 (fr) Proteine de cellule synoviale
JP2002525115A (ja) 発作、高血圧、糖尿病および肥満を予報および治療する、遺伝子およびタンパク質
JP2008537543A (ja) 神経変性状態に関与する遺伝子
US6900367B2 (en) Transgenic Drosophila melanogaster expressing a β42 in the eye
CA2494899A1 (fr) Polypeptides et acides nucleiques codant ceux-ci et utilisation de ceux-ci pour la prevention, le diagnostic ou le traitement de troubles du foie et du cancer epithelial
AU752962B2 (en) Therapeutic and diagnostic tools for impaired glucose tolerance conditions
US20060179497A1 (en) Methods to treat conditions associated with insulin signaling dysregulation
US20050085436A1 (en) Method to treat conditions associated with insulin signalling dysregulation
US20090016963A1 (en) Genes involved in neurodegenerative conditions
AU2001262988B2 (en) Presenilin enhancers
JP2004502444A (ja) 筋選択的カルシニューリン相互作用タンパク質（ｍｃｉｐ）に関連する方法および組成物
AU2001262988A1 (en) Presenilin enhancers
EP1571903A1 (fr) Methodes de traitement d'etats pathologiques associes au dysfonctionnement de la signalisation stimulee par l'insuline
EP1728424A2 (fr) Méthode pour le traitement de maladies liées à la dérégulation du système de signalisation de l'insuline
JP2007202554A (ja) カイコ２型濃核病ウイルス感受性遺伝子および抵抗性遺伝子、ならびにその利用
JP2007523608A (ja) サイクリックａｍｐ応答エレメントアクティベータータンパク質およびそれに関連する使用
WO2003062410A2 (fr) Proteine torero
WO1998043666A1 (fr) Proteine anti-oxydante 2, gene et procedes d'utilisation correspondants
JP2006320201A (ja) 気分障害又は関連障害による疾患症状を改善させる方法
JP2005500049A (ja) 有機化合物
JPWO2002064770A1 (ja) 新規スカベンジャー受容体クラスａ蛋白質
US20030119024A1 (en) Genes and proteins associated with T cell activation
WO2003048196A2 (fr) Moyens et procedes permettant de diagnostiquer et de traiter des malformations cranio-faciales
US20090233986A1 (en) Methods and compositions for using sax2
JP2004514435A (ja) 生体代謝の修飾

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050712

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20051116

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090324